Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
9.88
-0.24 (-2.42%)
At close: Sep 17, 2026, 4:00 PM EDT
9.99
+0.12 (1.16%)
After-hours: Sep 17, 2026, 6:48 PM EDT
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$5,160,000
Market Cap
19.23M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| Jasper Therapeutics | 22 |
| PDS Biotechnology | 21 |
| Lantern Pharma | 16 |
| Cellectar Biosciences | 11 |
| Cocrystal Pharma | 10 |
AKTX News
- 1 day ago - Akari price target adjusted at Alliance Global after transfer, reverse split - TheFly
- 9 days ago - Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums - GlobeNewsWire
- 21 days ago - Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics reports new AKTX-101 preclinical data - TheFly
- 4 weeks ago - Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics, Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Akari Therapeutics, Earnings release: Q2 2026 - Filings